Evaluation of Efficacy, Tolerability, and Pharmacokinetics of MYMD1 for Chronic Inflammation and Sarcopenia/Frailty
Status:
Recruiting
Trial end date:
2023-06-07
Target enrollment:
Participant gender:
Summary
The study will be conducted to investigate the efficacy, tolerability and pharmacokinetics of
MYMD1 in participants with chronic inflammation associated with sarcopenia/frailty, a
condition linked to elevated levels of proinflammatory cytokines.